使用工程化的LNP平台在体外向T细胞传递CAR mRNA和针对PD-1的siRNA，生成具有强大但短暂CAR表达和暂时细胞内在PD-1中断的人T细胞。 这些“超级”CAR-T细胞，在完成其功能后，可以恢复到正常患者T细胞的功能，极大地限制了由于CAR表达和PD-1抑制引起的脱靶效应的范围。

It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn ...

After hours: January 23 at 6:01:26 PM EST ...

Making the world smarter, happier, and richer.